Literature DB >> 6794675

Hemophilic dog model for evaluating therapeutic effectiveness of plasma protein fractions.

H S Kingdon, T M Hassell.   

Abstract

Therapeutic effectiveness of factor VIII inhibitor bypassing materials has been evaluated in dogs with hemophilia A. A standardized template gingival biopsy was performed using local anesthesia. Hemophilic dogs bled extensively from the biopsy site, whereas in normal dogs the wound was sealed within 5 + /- 2 min. If untreated, the hemophilic dogs frequently bled for several days. Factor VIII infusion stopped the bleeding promptly. Some experimental preparations of factor VIII inhibitor bypassing materials were shown to be therapeutically effective, whereas others were not. Intravascular thrombi could not be demonstrated histologically. The model should prove useful for evaluating factor VIII inhibitor bypassing materials and also for evaluating their mechanism of action.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6794675

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  5 in total

Review 1.  Adeno-associated virus vectors and hematology.

Authors:  D W Russell; M A Kay
Journal:  Blood       Date:  1999-08-01       Impact factor: 22.113

2.  A new mouse model for wound healing in hemophilia A.

Authors:  Guangwei Gao; Dhahiri Saidi Mashausi; Hema Negi; Dongsheng Li; Dawei Li
Journal:  Int J Clin Exp Pathol       Date:  2015-03-01

3.  Lessons Learned from Animal Models of Inherited Bleeding Disorders.

Authors:  Timothy C Nichols
Journal:  Hematol Educ       Date:  2014-06

4.  Use of human factor VIIa in the treatment of two hemophilia A patients with high-titer inhibitors.

Authors:  U Hedner; W Kisiel
Journal:  J Clin Invest       Date:  1983-06       Impact factor: 14.808

Review 5.  A review of current methods for assessing hemostasis in vivo and introduction to a potential alternative approach.

Authors:  Mallory R Scola; Leslie M Baggesen; Tim C Nichols; Nigel S Key; Caterina M Gallippi
Journal:  Thromb Res       Date:  2012-03-08       Impact factor: 3.944

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.